Income StatementBalance SheetCash FlowSegments
Neurocrine Biosciences logo

Neurocrine Biosciences Cash Flow Statement

Operating, investing, and financing cash movements

Neurocrine Biosciences generated $863.7M in operating cash flow over the trailing twelve months. After $34.8M in capital expenditures, free cash flow was $831.3M. Free cash flow increased 0.7% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$863.7MNet Cash From Investing (TTM)-$784.8MNet Cash From Financing (TTM)-$411.2MCapital Expenditures (TTM)$34.8MDepreciation And Amortization Cf (TTM)$26.6MNet Change In Cash (TTM)$72.4M
Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$15.7B
P/E Ratio23.52
ROE22.5%

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital expenditures incurred but not yet paid$1.4M$2.7M——$1.6M$1.4M
Income taxes paid$73.0M$600.0K$71.9M$1.1M$7.8M$300.0K
Capital expenditures incurred but not yet paid$1.4M$2.7M——$1.6M$1.4M
Capital Expenditures Incurred but Not Yet Paid$1.4M$2.7M——$1.6M$1.4M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Amortization of intangible assets$900.0K$1.0M$1.0M$1.0M$1.1M$100.0K
Amortization of Investment Discount and Premium$5.6M$4.6M$3.4M$2.7M$2.0M$1.3M
Accretion (amortization) of discounts and premiums on investments$5.6M$4.6M$3.4M$2.7M$2.0M$1.3M
Change in accounts payable$77.3M-$3.0M$30.9M$55.8M$76.5M-$14.3M
Change in accounts receivable$0.0$36.9M$79.7M$132.3M—$81.4M
Change in income taxes payable/receivable$55.1M$15.4M———$119.8M
Other working capital changes$100.0K$700.0K—$200.0K—$0.0
Deferred income taxes-$31.3M-$13.7M-$37.4M$168.3M$48.2M-$61.1M
Depreciation and amortization$6.2M$6.6M$6.3M$6.7M$6.4M$7.2M
Net gains (losses) on investments-$1.9M-$30.6M-$6.7M$30.6M—$25.3M
Gain (loss) on sale of assets—$0.0———$28.6M
Gain (loss) on disposal of group—$0.0———$28.6M
Accretion (Amortization) of Investment Discounts and Premiums$5.6M$4.6M$3.4M$2.7M$2.0M$1.3M
Gain (Loss) on Disposal Group—$0.0———$28.6M
Gain (Loss) on Disposal of Group (Not Discontinued Operation)—$0.0———$28.6M
Net cash from operating activities$242.5M$64.8M$102.0M$227.5M$388.4M$145.8M
Net income$103.1M$7.9M$107.5M$209.5M$153.7M$197.9M
Accretion (Amortization) of Discounts and Premiums, Investments$5.6M$4.6M$3.4M$2.7M$2.0M$1.3M
Amortization of capitalized software and acquired intangible assets$900.0K$1.0M$1.0M$1.0M$1.1M$100.0K
Non-cash operating lease expense—$7.2M$7.1M$6.6M—$2.7M
Operating lease right-of-use asset amortization—$7.2M$7.1M$6.6M—$2.7M
Non-cash lease expense$2.6M$6.7M$6.7M$6.7M$6.7M—
Pre-tax Gain on Disposal of Business—$0.0———$28.6M
Accretion (Amortization) of Investment Discounts and Premiums$5.6M$4.6M$3.4M$2.7M$2.0M$1.3M
Stock-based compensation$66.4M$52.8M$52.8M$53.7M$58.6M$57.2M
Gain (Loss) on Disposal Group Not Discontinued Operation—$0.0———$28.6M

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital expenditures$7.3M$10.7M$12.5M$13.2M$0.0$9.1M
Proceeds From Sale And Maturity Of Available For Sale Securities$250.8M$298.1M$298.6M$225.0M$267.7M$259.2M
Net cash from investing activities-$68.3M$14.2M-$29.0M-$196.7M-$52.9M-$506.2M
Proceeds from sale of businesses—$0.0———$63.2M
Purchases of investments$311.8M$273.2M$315.1M$408.5M$323.0M$819.5M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$235.2M$54.1M$89.5M$214.3M$390.8M$136.7M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net cash from financing activities-$290.0M-$117.9M-$3.3M——-$86.1M
Proceeds from issuance of common stock$10.0M$32.1M$14.4M$45.6M$37.3M$23.6M
Repurchases of common stock$300.0M$150.0M$17.7M——$54.0M
Taxes paid for net share settlement—$0.0———$55.7M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net increase (decrease) in cash-$116.1M-$38.9M$69.9M$76.2M$372.8M-$446.5M
Accrued payables for capital expenditures$1.4M$2.7M——$1.6M$1.4M